 | • レポートコード：MRC2308A130 • 出版社/出版日：Transparency Market Research / 2023年6月5日 • レポート形態：英文、PDF、179ページ • 納品方法：Eメール • 産業分類：医療 |
| Single User | ￥869,250 (USD5,795) | ▷ お問い合わせ |
| Multi User | ￥1,319,250 (USD8,795) | ▷ お問い合わせ |
| Corporate License | ￥1,769,250 (USD11,795) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 腫瘍-血液分子検査市場 - レポート範囲 TMRの調査レポート「腫瘍-血液分子検査の世界市場」は、2023年から2031年までの予測期間における市場の指標に関する貴重な洞察を得るために、過去だけでなく現在の成長動向と機会についても調査しています。2023年を基準年、2031年を予測年として、2017年から2031年までの世界の腫瘍-血液分子検査市場の収益を提供します。また、2023年から2031年までの世界の腫瘍-血液分子検査市場の年平均成長率（CAGR %）も掲載しています。 本レポートは広範な調査を経て作成されましました。主要オピニオンリーダー、業界リーダー、オピニオンメーカーへのインタビューを実施しました。二次調査では、主要企業の製品資料、年次報告書、プレスリリース、関連文書などを参照し、腫瘍-血液分子検査市場を理解しました。 二次調査には、インターネット情報源、政府機関の統計データ、ウェブサイト、業界団体なども含まれています。アナリストは、世界の腫瘍-血液分子検査市場の様々な属性を調査するために、トップダウンアプローチとボトムアップアプローチの組み合わせを採用しました。 本レポートには、調査範囲に含まれる様々なセグメントの成長動向のスナップショットとともに、詳細なエグゼクティブサマリーが含まれています。さらに、世界の腫瘍-血液分子検査市場における競争ダイナミクスの変化にも焦点を当てています。これらは、既存の市場プレイヤーだけでなく、世界の腫瘍-血液分子検査市場への参入に関心のある企業にとっても貴重なツールとなります。 当レポートでは、世界の腫瘍-血液分子検査市場の競争状況について調査しています。世界の腫瘍-血液分子検査市場で事業を展開する主要企業が特定され、これらの各企業が様々な属性でプロファイリングされています。会社概要、財務状況、最近の動向、SWOTなどが、本レポートで紹介する世界の腫瘍-血液分子検査市場におけるプレイヤーの項目です。 腫瘍-血液分子検査の世界市場レポートが回答した主要内容 - 予測期間中の全地域における腫瘍-血液分子検査の売上高/収益 - 世界の腫瘍-血液分子検査市場におけるビジネスチャンス - 市場における主な促進要因、阻害要因、機会、脅威 - 予測期間中に最も速いCAGRで拡大する地域市場 - 2031年に世界で最も高い収益を上げると予測されるセグメント - 予測期間中に最も高いCAGRで拡大すると予測されるセグメント - 世界市場で事業を展開する各社の市場ポジション 腫瘍-血液分子検査市場 - 調査目的と調査アプローチ 腫瘍-血液分子検査の世界市場に関する包括的なレポートは、概要から始まり、調査範囲と目的が続きます。本レポートでは、本調査の目的、市場で事業を展開する主要ベンダーと販売業者、製品承認に関する規制シナリオについて詳細に解説しています。 本レポートは、読みやすさを考慮し、各セクションを章ごとに分割したレイアウトになっています。本レポートは、グラフや表が適切に散りばめられた網羅的なコレクションで構成されています。主要セグメントの実績値と予測値を図式化し、読者に視覚的に訴えます。また、過去と予測期間末の主要セグメントの市場シェアの比較も可能です。 当レポートでは、世界の腫瘍-血液分子検査市場を製品、エンドユーザー、地域の観点から分析しています。各基準の主要セグメントを詳細に調査し、2031年末時点の各セグメントにおける市場シェアを掲載しています。このような貴重な洞察により、市場関係者は、世界の腫瘍-血液分子検査市場への投資について、情報に基づいたビジネス上の意思決定を行うことができます。 |
1. 序論
2. 仮定＆調査手法
3. エグゼクティブサマリー：世界の腫瘍-血液分子検査市場
4. 市場概要
5. キーインサイト
6. 世界の腫瘍-血液分子検査市場分析＆予測：血液がん種類別
7. 世界の腫瘍-血液分子検査市場分析＆予測：血液がんバイオマーカー別
8. 世界の腫瘍-血液分子検査市場分析＆予測：技術別
9. 世界の腫瘍-血液分子検査市場分析＆予測：エンドユーザー別
10. 世界の腫瘍-血液分子検査市場分析＆予測：地域別
11. 北米の腫瘍-血液分子検査市場分析＆予測
12. ヨーロッパの腫瘍-血液分子検査市場分析＆予測
13. アジア太平洋の腫瘍-血液分子検査市場分析＆予測
14. 中南米の腫瘍-血液分子検査市場分析＆予測
15. 中東・アフリカの腫瘍-血液分子検査市場分析＆予測
16. 競争状況
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Onco-hematology Molecular Testing Market
4. Market Overview
4.1. Introduction
4.1.1. Segment Definition
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Onco-hematology Molecular Testing Market Analysis and Forecast, 2017-2031
5. Key Insights
5.1. Overview of Onco-hematology Molecular Testing Market
5.2. Key Product/ Brand Analysis
5.3. Pipeline Analysis
5.4. COVID-19 Pandemic Impact on Industry
6. Global Onco-hematology Molecular Testing Market Analysis and Forecast, by Blood Cancer Type
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Blood Cancer Type, 2017-2031
6.3.1. Chronic Myeloid Leukemia
6.3.1.1. Polycythemia Vera
6.3.1.2. Essential Thrombocythaemia
6.3.1.3. Myelofibrosis
6.3.2. Myeloproliferative Neoplasms
6.3.3. Acute Myeloid Leukemia
6.3.4. Acute Lymphoblastic Leukemia
6.4. Market Attractiveness Analysis, by Blood Cancer Type
7. Global Onco-hematology Molecular Testing Market Analysis and Forecast, by Blood Cancer Biomarker
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Blood Cancer Biomarker, 2017-2031
7.3.1. BCR-ABL1 MBCR
7.3.2. JAK2
7.3.3. CALR
7.3.4. MPL
7.3.5. PML-RARA
7.3.6. NPM1
7.3.7. RUNX1-RUNX1T1
7.3.8. CBFB-MYH11
7.3.9. BCR-ABL1 mbcr
7.4. Market Attractiveness Analysis, by Blood Cancer Biomarker
8. Global Onco-hematology Molecular Testing Market Analysis and Forecast, by Technology
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Technology, 2017-2031
8.3.1. qPCR
8.3.2. dPCR
8.3.3. Next-Generation Sequencing
8.3.4. Others
8.4. Market Attractiveness Analysis, by Technology
9. Global Onco-hematology Molecular Testing Market Analysis and Forecast, by End-user
9.1. Introduction & Definition
9.2. Key Findings/Developments
9.3. Market Value Forecast, by End-user, 2017-2031
9.3.1. National Reference Lab/Specialty Lab
9.3.2. University Hospital/Oncology Center
9.3.3. Community Hospital/IDN (Regional/National
9.4. Market Attractiveness Analysis, by End-user
10. Global Onco-hematology Molecular Testing Market Analysis and Forecast, by Region
10.1. Key Findings
10.2. Market Value Forecast, by Region, 2017-2031
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3. Market Attractiveness Analysis, by Region
11. North America Onco-hematology Molecular Testing Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Blood Cancer Type, 2017-2031
11.2.1. Chronic Myeloid Leukemia
11.2.1.1. Polycythemia Vera
11.2.1.2. Essential Thrombocythaemia
11.2.1.3. Myelofibrosis
11.2.2. Myeloproliferative Neoplasms
11.2.3. Acute Myeloid Leukemia
11.2.4. Acute Lymphoblastic Leukemia
11.3. Market Value Forecast, by Blood Cancer Biomarker, 2017-2031
11.3.1. BCR-ABL1 MBCR
11.3.2. JAK2
11.3.3. CALR
11.3.4. MPL
11.3.5. PML-RARA
11.3.6. NPM1
11.3.7. RUNX1-RUNX1T1
11.3.8. CBFB-MYH11
11.3.9. BCR-ABL1 mbcr
11.4. Market Value Forecast, by Technology, 2017-2031
11.4.1. qPCR
11.4.2. dPCR
11.4.3. Next-Generation Sequencing
11.4.4. Others
11.5. Market Value Forecast, by End-user, 2017-2031
11.5.1. National Reference Lab/Specialty Lab
11.5.2. University Hospital/Oncology Center
11.5.3. Community Hospital/IDN (Regional/National
11.6. Market Value Forecast, by Country, 2017-2031
11.6.1. U.S.
11.6.2. Canada
11.7. Market Attractiveness Analysis
11.7.1. By Blood Cancer Type
11.7.2. By Blood Cancer Biomarker
11.7.3. By Technology
11.7.4. By End-user
11.7.5. By Country
12. Europe Onco-hematology Molecular Testing Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Blood Cancer Type, 2017-2031
12.2.1. Chronic Myeloid Leukemia
12.2.1.1. Polycythemia Vera
12.2.1.2. Essential Thrombocythaemia
12.2.1.3. Myelofibrosis
12.2.2. Myeloproliferative Neoplasms
12.2.3. Acute Myeloid Leukemia
12.2.4. Acute Lymphoblastic Leukemia
12.3. Market Value Forecast, by Blood Cancer Biomarker, 2017-2031
12.3.1. BCR-ABL1 MBCR
12.3.2. JAK2
12.3.3. CALR
12.3.4. MPL
12.3.5. PML-RARA
12.3.6. NPM1
12.3.7. RUNX1-RUNX1T1
12.3.8. CBFB-MYH11
12.3.9. BCR-ABL1 mbcr
12.4. Market Value Forecast, by Technology, 2017-2031
12.4.1. qPCR
12.4.2. dPCR
12.4.3. Next-Generation Sequencing
12.4.4. Others
12.5. Market Value Forecast, by End-user, 2017-2031
12.5.1. National Reference Lab/Specialty Lab
12.5.2. University Hospital/Oncology Center
12.5.3. Community Hospital/IDN (Regional/National
12.6. Market Value Forecast, by Country/Sub-region, 2017-2031
12.6.1. Germany
12.6.2. U.K.
12.6.3. France
12.6.4. Italy
12.6.5. Spain
12.6.6. Rest of Europe
12.7. Market Attractiveness Analysis
12.7.1. By Blood Cancer Type
12.7.2. By Blood Cancer Biomarker
12.7.3. By Technology
12.7.4. By End-user
12.7.5. By Country/Sub-region
13. Asia Pacific Onco-hematology Molecular Testing Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Blood Cancer Type, 2017-2031
13.2.1. Chronic Myeloid Leukemia
13.2.1.1. Polycythemia Vera
13.2.1.2. Essential Thrombocythaemia
13.2.1.3. Myelofibrosis
13.2.2. Myeloproliferative Neoplasms
13.2.3. Acute Myeloid Leukemia
13.2.4. Acute Lymphoblastic Leukemia
13.3. Market Value Forecast, by Blood Cancer Biomarker, 2017-2031
13.3.1. BCR-ABL1 MBCR
13.3.2. JAK2
13.3.3. CALR
13.3.4. MPL
13.3.5. PML-RARA
13.3.6. NPM1
13.3.7. RUNX1-RUNX1T1
13.3.8. CBFB-MYH11
13.3.9. BCR-ABL1 mbcr
13.4. Market Value Forecast, by Technology, 2017-2031
13.4.1. qPCR
13.4.2. dPCR
13.4.3. Next-Generation Sequencing
13.4.4. Others
13.5. Market Value Forecast, by End-user, 2017-2031
13.5.1. National Reference Lab/Specialty Lab
13.5.2. University Hospital/Oncology Center
13.5.3. Community Hospital/IDN (Regional/National
13.6. Market Value Forecast, by Country/Sub-region, 2017-2031
13.6.1. China
13.6.2. Japan
13.6.3. India
13.6.4. Australia & New Zealand
13.6.5. Rest of Asia Pacific
13.7. Market Attractiveness Analysis
13.7.1. By Blood Cancer Type
13.7.2. By Blood Cancer Biomarker
13.7.3. By Technology
13.7.4. By End-user
13.7.5. By Country/Sub-region
14. Latin America Onco-hematology Molecular Testing Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Blood Cancer Type, 2017-2031
14.2.1. Chronic Myeloid Leukemia
14.2.1.1. Polycythemia Vera
14.2.1.2. Essential Thrombocythaemia
14.2.1.3. Myelofibrosis
14.2.2. Myeloproliferative Neoplasms
14.2.3. Acute Myeloid Leukemia
14.2.4. Acute Lymphoblastic Leukemia
14.3. Market Value Forecast, by Blood Cancer Biomarker, 2017-2031
14.3.1. BCR-ABL1 MBCR
14.3.2. JAK2
14.3.3. CALR
14.3.4. MPL
14.3.5. PML-RARA
14.3.6. NPM1
14.3.7. RUNX1-RUNX1T1
14.3.8. CBFB-MYH11
14.3.9. BCR-ABL1 mbcr
14.4. Market Value Forecast, by Technology, 2017-2031
14.4.1. qPCR
14.4.2. dPCR
14.4.3. Next-Generation Sequencing
14.4.4. Others
14.5. Market Value Forecast, by End-user, 2017-2031
14.5.1. National Reference Lab/Specialty Lab
14.5.2. University Hospital/Oncology Center
14.5.3. Community Hospital/IDN (Regional/National
14.6. Market Value Forecast, by Country/Sub-region, 2017-2031
14.6.1. Brazil
14.6.2. Mexico
14.6.3. Rest of Latin America
14.7. Market Attractiveness Analysis
14.7.1. By Blood Cancer Type
14.7.2. By Blood Cancer Biomarker
14.7.3. By Technology
14.7.4. By End-user
14.7.5. By Country/Sub-region
15. Middle East & Africa Onco-hematology Molecular Testing Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Blood Cancer Type, 2017-2031
15.2.1. Chronic Myeloid Leukemia
15.2.1.1. Polycythemia Vera
15.2.1.2. Essential Thrombocythaemia
15.2.1.3. Myelofibrosis
15.2.2. Myeloproliferative Neoplasms
15.2.3. Acute Myeloid Leukemia
15.2.4. Acute Lymphoblastic Leukemia
15.3. Market Value Forecast, by Blood Cancer Biomarker, 2017-2031
15.3.1. BCR-ABL1 MBCR
15.3.2. JAK2
15.3.3. CALR
15.3.4. MPL
15.3.5. PML-RARA
15.3.6. NPM1
15.3.7. RUNX1-RUNX1T1
15.3.8. CBFB-MYH11
15.3.9. BCR-ABL1 mbcr
15.4. Market Value Forecast, by Technology, 2017-2031
15.4.1. qPCR
15.4.2. dPCR
15.4.3. Next-Generation Sequencing
15.4.4. Others
15.5. Market Value Forecast, by End-user, 2017-2031
15.5.1. National Reference Lab/Specialty Lab
15.5.2. University Hospital/Oncology Center
15.5.3. Community Hospital/IDN (Regional/National
15.6. Market Value Forecast, by Country/Sub-region, 2017-2031
15.6.1. GCC Countries
15.6.2. South Africa
15.6.3. Rest of Middle East & Africa
15.7. Market Attractiveness Analysis
15.7.1. By Blood Cancer Type
15.7.2. By Blood Cancer Biomarker
15.7.3. By Technology
15.7.4. By End-user
15.7.5. By Country/Sub-region
16. Competition Landscape
16.1. Market Player – Competition Matrix (by tier and size of companies)
16.2. Market Share Analysis, by Company, 2022
16.3. Company Profiles
16.3.1. Asuragen, Inc.
16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.1.2. Product Portfolio
16.3.1.3. Financial Overview
16.3.1.4. SWOT Analysis
16.3.1.5. Strategic Overview
16.3.2. Bio-Rad Laboratories, Inc.
16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.2.2. Product Portfolio
16.3.2.3. Financial Overview
16.3.2.4. SWOT Analysis
16.3.2.5. Strategic Overview
16.3.3. ICON plc
16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.3.2. Product Portfolio
16.3.3.3. Financial Overview
16.3.3.4. SWOT Analysis
16.3.3.5. Strategic Overview
16.3.4. Integrated DNA Technologies, Inc. (ArcherDx, Inc.)
16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.4.2. Product Portfolio
16.3.4.3. Financial Overview
16.3.4.4. SWOT Analysis
16.3.4.5. Strategic Overview
16.3.5. Invivoscribe, Inc.
16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.5.2. Product Portfolio
16.3.5.3. Financial Overview
16.3.5.4. SWOT Analysis
16.3.5.5. Strategic Overview
16.3.6. QIAGEN N.V.
16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.6.2. Product Portfolio
16.3.6.3. Financial Overview
16.3.6.4. SWOT Analysis
16.3.6.5. Strategic Overview
16.3.7. Thermo Fisher Scientific, Inc.
16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.7.2. Product Portfolio
16.3.7.3. Financial Overview
16.3.7.4. SWOT Analysis
16.3.7.5. Strategic Overview
16.3.8. Cepheid
16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.8.2. Product Portfolio
16.3.8.3. Financial Overview
16.3.8.4. SWOT Analysis
16.3.8.5. Strategic Overview
16.3.9. Illumina, Inc.
16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.9.2. Product Portfolio
16.3.9.3. Financial Overview
16.3.9.4. SWOT Analysis
16.3.9.5. Strategic Overview
Table 01: Global Onco-hematology Molecular Testing Market Value (US$ Mn) Forecast, by Blood Cancer Type, 2017-2031
Table 02: Global Onco-hematology Molecular Testing Market Value (US$ Mn) Forecast, by Blood Cancer Biomarker, 2017‒2031
Table 03: Global Onco-hematology Molecular Testing Market Value (US$ Mn) Forecast, by Technology, 2017-2031
Table 04: Global Onco-hematology Molecular Testing Market Value (US$ Mn) Forecast, by End-user, 2017-2031
Table 05: Global Onco-hematology Molecular Testing Market Value (US$ Mn) Forecast, by Region, 2017-2031
Table 06: North America Onco-hematology Molecular Testing Market Value (US$ Mn) Forecast, by Country, 2017-2031
Table 07: North America Onco-hematology Molecular Testing Market Value (US$ Mn) Forecast, by Blood Cancer Type, 2017-2031
Table 08: North America Onco-hematology Molecular Testing Market Value (US$ Mn) Forecast, by Blood Cancer Biomarker, 2017‒2031
Table 09: North America Onco-hematology Molecular Testing Market Value (US$ Mn) Forecast, by Technology, 2017-2031
Table 10: North America Onco-hematology Molecular Testing Market Value (US$ Mn) Forecast, by End-user, 2017-2031
Table 11: Europe Onco-hematology Molecular Testing Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 12: Europe Onco-hematology Molecular Testing Market Value (US$ Mn) Forecast, by Blood Cancer Type, 2017-2031
Table 13: Europe Onco-hematology Molecular Testing Market Value (US$ Mn) Forecast, by Blood Cancer Biomarker, 2017‒2031
Table 14: Europe Onco-hematology Molecular Testing Market Value (US$ Mn) Forecast, by Technology, 2017-2031
Table 15: Europe Onco-hematology Molecular Testing Market Value (US$ Mn) Forecast, by End-user, 2017-2031
Table 16: Asia Pacific Onco-hematology Molecular Testing Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 17: Asia Pacific Onco-hematology Molecular Testing Market Value (US$ Mn) Forecast, by Blood Cancer Type, 2017-2031
Table 18: Asia Pacific Onco-hematology Molecular Testing Market Value (US$ Mn) Forecast, by Blood Cancer Biomarker, 2017‒2031
Table 19: Asia Pacific Onco-hematology Molecular Testing Market Value (US$ Mn) Forecast, by Technology, 2017-2031
Table 20: Asia Pacific Onco-hematology Molecular Testing Market Value (US$ Mn) Forecast, by End-user, 2017-2031
Table 21: Latin America Onco-hematology Molecular Testing Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 22: Latin America Onco-hematology Molecular Testing Market Value (US$ Mn) Forecast, by Blood Cancer Type, 2017-2031
Table 23: Latin America Onco-hematology Molecular Testing Market Value (US$ Mn) Forecast, by Blood Cancer Biomarker, 2017‒2031
Table 24: Latin America Onco-hematology Molecular Testing Market Value (US$ Mn) Forecast, by Technology, 2017-2031
Table 25: Latin America Onco-hematology Molecular Testing Market Value (US$ Mn) Forecast, by End-user, 2017-2031
Table 26: Middle East & Africa Onco-hematology Molecular Testing Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 27: Middle East & Africa Onco-hematology Molecular Testing Market Value (US$ Mn) Forecast, by Blood Cancer Type, 2017-2031
Table 28: Middle East & Africa Onco-hematology Molecular Testing Market Value (US$ Mn) Forecast, by Blood Cancer Biomarker, 2017‒2031
Table 29: Middle East & Africa Onco-hematology Molecular Testing Market Value (US$ Mn) Forecast, by Technology, 2017-2031
Table 30: Middle East & Africa Onco-hematology Molecular Testing Market Value (US$ Mn) Forecast, by End-user, 2017-2031